Here are the 10-Q quarterly reports from Alpha Cognition Inc. (ACOG) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow ACOG and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ACOG filings page.
Alpha Cognition Inc. reported strong top-line growth in the quarter ended June 30, 2026 as its Alzheimer’s drug ZUNVEYL scaled. Total revenue rose to $6.1 million for the quarter and $9.6 million year-to-date, driven by higher prescription volumes and a higher wholesale acquisition cost of $869.36 per month.
Gross profit grew to $5.7 million in the quarter, but the company remains unprofitable as it invests in commercialization and development. Net loss was $8.8 million for the quarter and $15.3 million for the first half of 2026. Operating expenses reached $13.5 million in Q2, led by selling, general and administrative spending of $11.4 million and research and development of $2.0 million.
Cash and cash equivalents were $41.4 million against current liabilities of $6.4 million, with operating cash outflow of $18.7 million in the first half. Management believes current cash will fund operations for at least 12 months but expects to seek additional capital, including use of a $75 million at-the-market facility that has not yet been utilized.
Alpha Cognition Inc. reported first-quarter 2026 results showing early commercial traction but higher losses. Total revenue was $3.53 million, up 21% year over year, driven by a jump in ZUNVEYL product sales to $3.50 million, while licensing revenue fell to $0.03 million.
Operating expenses rose to $11.63 million, mainly from expanding sales, marketing, and headcount to support the ZUNVEYL launch, resulting in a net loss of $6.48 million versus $1.73 million a year earlier. Cash and cash equivalents were $54.25 million, and management believes this is sufficient for at least 12 months, though additional capital will likely be needed for ongoing commercialization and R&D.
The company disclosed a material weakness in internal control over financial reporting related to complex instruments and segregation of duties and is implementing enhanced review procedures and external technical support. Alpha Cognition remains focused on building the ZUNVEYL franchise and advancing its preclinical neurodegenerative pipeline.